BR112020011205A8 - Formulações de composições de vacina contra o vírus da dengue - Google Patents
Formulações de composições de vacina contra o vírus da dengueInfo
- Publication number
- BR112020011205A8 BR112020011205A8 BR112020011205A BR112020011205A BR112020011205A8 BR 112020011205 A8 BR112020011205 A8 BR 112020011205A8 BR 112020011205 A BR112020011205 A BR 112020011205A BR 112020011205 A BR112020011205 A BR 112020011205A BR 112020011205 A8 BR112020011205 A8 BR 112020011205A8
- Authority
- BR
- Brazil
- Prior art keywords
- dengue virus
- formulations
- live attenuated
- vaccine compositions
- compositions against
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Virology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Abstract
A presente invenção refere-se a formulações de vacina contra o vírus da dengue compreendendo pelo menos um vírus da dengue vivo atenuado ou flavivírus quimérico vivo atenuado, um tampão, um açúcar, um derivado de celulose, um glicol ou álcool de açúcar, opcionalmente um sal alcalino ou álcali e um aminoácido; e formulações de vacina contra o vírus da dengue compreendendo pelo menos um vírus da dengue vivo atenuado ou flavivírus quimérico vivo atenuado, um tampão, um açúcar de pelo menos 150 mg/ml, um veículo e, opcionalmente, um sal alcalino ou álcali e um aminoácido.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762595842P | 2017-12-07 | 2017-12-07 | |
US62/595,842 | 2017-12-07 | ||
PCT/US2018/063541 WO2019112921A1 (en) | 2017-12-07 | 2018-12-03 | Formulations of dengue virus vaccine compositions |
Publications (2)
Publication Number | Publication Date |
---|---|
BR112020011205A2 BR112020011205A2 (pt) | 2020-11-17 |
BR112020011205A8 true BR112020011205A8 (pt) | 2023-02-07 |
Family
ID=66750326
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112020011205A BR112020011205A8 (pt) | 2017-12-07 | 2018-12-03 | Formulações de composições de vacina contra o vírus da dengue |
Country Status (23)
Country | Link |
---|---|
US (3) | US20200390877A1 (pt) |
EP (1) | EP3720487A1 (pt) |
JP (1) | JP7042341B2 (pt) |
KR (1) | KR102494651B1 (pt) |
CN (2) | CN117752780A (pt) |
AU (1) | AU2018381213B2 (pt) |
BR (1) | BR112020011205A8 (pt) |
CA (1) | CA3083772A1 (pt) |
CL (1) | CL2020001463A1 (pt) |
CO (1) | CO2020006836A2 (pt) |
CR (1) | CR20200242A (pt) |
DO (1) | DOP2020000098A (pt) |
EA (1) | EA202091398A1 (pt) |
EC (1) | ECSP20032084A (pt) |
GE (1) | GEP20237539B (pt) |
IL (1) | IL274897A (pt) |
JO (1) | JOP20200140A1 (pt) |
MA (1) | MA51060A (pt) |
MX (1) | MX2020005857A (pt) |
NI (1) | NI202000039A (pt) |
PE (1) | PE20210654A1 (pt) |
SG (1) | SG11202005251VA (pt) |
WO (1) | WO2019112921A1 (pt) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MA51060A (fr) | 2017-12-07 | 2021-03-17 | Merck Sharp & Dohme | Formulations de compositions de vaccin contre le virus de la dengue |
CN118215488A (zh) * | 2021-10-20 | 2024-06-18 | 舒万诺知识产权公司 | 含有磷酸盐和精氨酸的组合物以及此类组合物用于毒力抑制的递送 |
WO2024073362A2 (en) * | 2022-09-29 | 2024-04-04 | Board Of Regents, The University Of Texas System | Methods and compositions for transport, storage, and delivery of nucleic acids and other molecules |
WO2024086605A1 (en) | 2022-10-18 | 2024-04-25 | Takeda Vaccines, Inc. | Dengue vaccine formulation |
Family Cites Families (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2254055T3 (es) | 1991-09-19 | 2006-06-16 | The United States Of America, As Represented By The Secretary, Departm. Of Health And Human Services | Flavivirus quimericos y/o de crecimiento restringido. |
FR2702660B1 (fr) * | 1993-03-17 | 1995-05-24 | Karl Simpson | Compositions thérapeutiques stabilisées et leur procédé de préparation. |
US6254873B1 (en) | 1995-04-17 | 2001-07-03 | The United States Of America As Represented By The Secretary Of The Army | Inactivated dengue virus vaccine |
US6190859B1 (en) | 1995-04-17 | 2001-02-20 | The United States Of America As Represented By The Secretary Of The Army | Method and kit for detection of dengue virus |
US6432411B1 (en) | 1999-07-13 | 2002-08-13 | Hawaii Biotechnology Group | Recombinant envelope vaccine against flavivirus infection |
US20030180352A1 (en) * | 1999-11-23 | 2003-09-25 | Patel Mahesh V. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
ES2533085T3 (es) | 2001-05-22 | 2015-04-07 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Desarrollo de mutaciones útiles para atenuar virus del dengue y virus del dengue quiméricos |
US7476390B2 (en) * | 2002-02-26 | 2009-01-13 | Maxygen, Inc. | Flavivirus antigens |
MXPA04009394A (es) * | 2002-03-26 | 2005-01-25 | Inmunex Corp | Metodos para utilizar ligando flt3 en procedimientos de inmunizacion. |
WO2003092592A2 (en) | 2002-05-03 | 2003-11-13 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Dengue tetravalent vaccine containing a common 30 nucleotide deletion in the 3'-utr of dengue types 1,2,3, and 4, or antigenic chimeric dengue viruses 1,2,3, and 4 |
US20050123550A1 (en) | 2003-05-12 | 2005-06-09 | Laurent Philippe E. | Molecules enhancing dermal delivery of influenza vaccines |
CN101128216A (zh) * | 2005-01-05 | 2008-02-20 | 费城健康和教育公司 | 输送载体、生物活性物质和病毒疫苗 |
EP1896069B1 (en) | 2005-06-24 | 2013-03-13 | Intervet International BV | Inactivated chimeric vaccines and related methods of use |
KR20080059289A (ko) | 2005-10-04 | 2008-06-26 | 알크-아벨로 에이/에스 | 고체 백신 제형 |
CN101296705A (zh) * | 2005-10-04 | 2008-10-29 | 阿尔克-阿贝洛有限公司 | 固体疫苗制剂 |
US8337860B2 (en) | 2006-08-15 | 2012-12-25 | The United States Of America, As Represented By The Secretary Of The Department Of Health & Human Services | Development of dengue virus vaccine components |
US20080275030A1 (en) * | 2007-01-19 | 2008-11-06 | Sveinbjorn Gizurarson | Methods and Compositions for the Delivery of a Therapeutic Agent |
HUE031617T2 (en) | 2007-04-06 | 2017-07-28 | Takeda Vaccines Inc | Methods and preparations for live attenuated viruses |
EP2143440A1 (fr) | 2008-07-09 | 2010-01-13 | Sanofi Pasteur | Agent stabilisant et composition vaccinale comprenant un ou plusieurs flavivirus vivants atténués |
CN102215865B (zh) * | 2008-09-24 | 2013-10-30 | 米迪缪尼有限公司 | 病毒纯化方法 |
WO2010037402A1 (en) | 2008-10-02 | 2010-04-08 | Dako Denmark A/S | Molecular vaccines for infectious disease |
JP2012520084A (ja) | 2009-03-13 | 2012-09-06 | レンチゲン コーポレイション | 非組み込み型レトロウイルスベクターワクチン |
GB201002419D0 (en) * | 2010-02-12 | 2010-03-31 | Isis Innovation | Stable live vaccine formulations |
JP6018575B2 (ja) | 2010-10-29 | 2016-11-02 | メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. | デングウイルス組換えサブユニットスワクチン |
JP2014515367A (ja) | 2011-05-26 | 2014-06-30 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | 不活性化デング熱ウイルスワクチン |
ES2729967T3 (es) | 2012-02-07 | 2019-11-07 | Infectious Disease Res Inst | Formulaciones de adyuvante mejoradas que comprenden agonistas de TLR4 y métodos para usar las mismas |
US9314519B2 (en) * | 2012-08-21 | 2016-04-19 | Intervet Inc. | Liquid stable virus vaccines |
US9974850B2 (en) * | 2013-01-25 | 2018-05-22 | Board Of Regents, The University Of Texas System | Immunogenic compositions and uses thereof |
US9254332B2 (en) * | 2013-03-15 | 2016-02-09 | Arecor Limited | Stable aqueous formulations of adenovirus vectors |
SG11201510266SA (en) | 2013-06-21 | 2016-01-28 | Merck Sharp & Dohme | Dengue virus vaccine compositions and methods of use thereof |
US9782470B2 (en) | 2013-10-16 | 2017-10-10 | Merck Sharp & Dohme Corp. | Method of obtaining thermostable dried vaccine formulations |
EP3060247A1 (en) | 2013-10-25 | 2016-08-31 | Leukocare Ag | A novel method for the production of stabile vaccines |
WO2015093452A1 (ja) | 2013-12-16 | 2015-06-25 | 武田薬品工業株式会社 | マイクロニードル |
US11801223B2 (en) * | 2013-12-31 | 2023-10-31 | Access To Advanced Health Institute | Single vial vaccine formulations |
WO2015130157A1 (en) | 2014-02-28 | 2015-09-03 | Universiti Malaya | Enhancement of dengue virus production |
AU2015369875A1 (en) | 2014-12-22 | 2017-06-15 | Merck Sharp & Dohme Corp. | Dengue virus vaccine compositions and methods of use thereof |
EP3303571A4 (en) * | 2015-06-04 | 2018-10-17 | The University of Hong Kong | Live-attenuated virus and methods of production and use |
US20180296663A1 (en) * | 2015-06-17 | 2018-10-18 | Curevac Ag | Vaccine composition |
US10004795B2 (en) | 2015-09-08 | 2018-06-26 | Fundacao Butantan | Process for preparing an attenuated tetravalent dengue vaccine |
EP3355916A4 (en) * | 2015-09-30 | 2018-08-29 | Panacea Biotec Limited | Stable live attenuated recombinant dengue vaccine |
BE1024160B9 (fr) | 2015-12-22 | 2017-12-06 | Glaxosmithkline Biologicals Sa | Formulation immunogène |
WO2017165736A1 (en) | 2016-03-25 | 2017-09-28 | Visterra, Inc. | Formulation of antibody molecules to dengue virus |
AU2017250696A1 (en) * | 2016-04-13 | 2018-11-22 | Takeda Vaccines, Inc. | Compositions and methods of vaccination against dengue virus in children and young adults |
TW202309276A (zh) | 2016-08-03 | 2023-03-01 | 美商武田疫苗股份有限公司 | 用於與經改良之調配物一起穩定黃病毒的組成物及方法 |
CA3037337A1 (en) | 2016-09-19 | 2018-03-22 | Vaxess Technologies, Inc. | Vaccine formulations with increased stability |
WO2018183426A1 (en) | 2017-03-30 | 2018-10-04 | Merck Sharp & Dohme Corp. | Addition of nucleases directly to cell culture to facilitate digestion and clearance of host cell nucleic acids |
US11660333B2 (en) | 2017-10-16 | 2023-05-30 | Serum Institute Of India Private Limited | Stable vaccine compositions comprising inter alia live attenuated recombinant flavivirus and process for preparation thereof |
MA51060A (fr) | 2017-12-07 | 2021-03-17 | Merck Sharp & Dohme | Formulations de compositions de vaccin contre le virus de la dengue |
-
2018
- 2018-12-03 MA MA051060A patent/MA51060A/fr unknown
- 2018-12-03 SG SG11202005251VA patent/SG11202005251VA/en unknown
- 2018-12-03 CN CN202311806711.3A patent/CN117752780A/zh active Pending
- 2018-12-03 EP EP18887100.8A patent/EP3720487A1/en active Pending
- 2018-12-03 EA EA202091398A patent/EA202091398A1/ru unknown
- 2018-12-03 JO JOP/2020/0140A patent/JOP20200140A1/ar unknown
- 2018-12-03 JP JP2020530648A patent/JP7042341B2/ja active Active
- 2018-12-03 BR BR112020011205A patent/BR112020011205A8/pt unknown
- 2018-12-03 AU AU2018381213A patent/AU2018381213B2/en active Active
- 2018-12-03 PE PE2020000684A patent/PE20210654A1/es unknown
- 2018-12-03 WO PCT/US2018/063541 patent/WO2019112921A1/en unknown
- 2018-12-03 US US16/769,837 patent/US20200390877A1/en not_active Abandoned
- 2018-12-03 GE GEAP201815384A patent/GEP20237539B/en unknown
- 2018-12-03 CA CA3083772A patent/CA3083772A1/en active Pending
- 2018-12-03 CR CR20200242A patent/CR20200242A/es unknown
- 2018-12-03 CN CN201880079043.XA patent/CN111447947B/zh active Active
- 2018-12-03 MX MX2020005857A patent/MX2020005857A/es unknown
- 2018-12-03 KR KR1020207019204A patent/KR102494651B1/ko active IP Right Grant
-
2020
- 2020-05-25 IL IL274897A patent/IL274897A/en unknown
- 2020-05-29 DO DO2020000098A patent/DOP2020000098A/es unknown
- 2020-06-01 CL CL2020001463A patent/CL2020001463A1/es unknown
- 2020-06-01 NI NI202000039A patent/NI202000039A/es unknown
- 2020-06-02 CO CONC2020/0006836A patent/CO2020006836A2/es unknown
- 2020-06-12 EC ECSENADI202032084A patent/ECSP20032084A/es unknown
-
2022
- 2022-07-26 US US17/815,037 patent/US11883480B2/en active Active
-
2023
- 2023-12-06 US US18/530,421 patent/US20240131144A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
CL2020001463A1 (es) | 2020-09-25 |
IL274897A (en) | 2020-07-30 |
US20200390877A1 (en) | 2020-12-17 |
MA51060A (fr) | 2021-03-17 |
CN117752780A (zh) | 2024-03-26 |
EA202091398A1 (ru) | 2020-09-01 |
SG11202005251VA (en) | 2020-07-29 |
GEP20237539B (en) | 2023-09-11 |
EP3720487A1 (en) | 2020-10-14 |
MX2020005857A (es) | 2020-09-09 |
CR20200242A (es) | 2020-07-17 |
CN111447947B (zh) | 2024-01-12 |
AU2018381213A1 (en) | 2020-06-11 |
JP2021505588A (ja) | 2021-02-18 |
KR20200096272A (ko) | 2020-08-11 |
CA3083772A1 (en) | 2019-06-13 |
NI202000039A (es) | 2020-09-24 |
US20240131144A1 (en) | 2024-04-25 |
BR112020011205A2 (pt) | 2020-11-17 |
US11883480B2 (en) | 2024-01-30 |
AU2018381213B2 (en) | 2022-03-17 |
DOP2020000098A (es) | 2020-08-31 |
ECSP20032084A (es) | 2020-08-31 |
KR102494651B1 (ko) | 2023-01-31 |
PE20210654A1 (es) | 2021-03-31 |
CO2020006836A2 (es) | 2020-06-19 |
US20230061673A1 (en) | 2023-03-02 |
CN111447947A (zh) | 2020-07-24 |
WO2019112921A1 (en) | 2019-06-13 |
JP7042341B2 (ja) | 2022-03-25 |
JOP20200140A1 (ar) | 2022-10-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112020011205A8 (pt) | Formulações de composições de vacina contra o vírus da dengue | |
CY1117941T1 (el) | Υψηλης συγκεντρωσης φapμαkeytika σκευασματα που περιλαμβανουν το αντισωμα κatα cd20 | |
CL2018001474A1 (es) | Mezcla seca que comprende sal de alginato; goma vegetal hidrocoloide de galactamanano; y almidon para la fabricacion de una composicion de alginato para envoltura de productos alimenticios que ademas comprende: poliol; humo liquido; y un agente amortiguador tal como glucono-delta-lactona, ácido acético, y carbonato de sodio (divisional de 408-2017). | |
PH12017500844A1 (en) | Stable protein solution formulation containing high concentration of an anti-vegf antibody | |
CY1114185T1 (el) | Υποδοριο σκευασμα αντισωματος αντι-her2 | |
BR112018068683A2 (pt) | glicosídeos de esteviol altamente solúveis | |
BR112016006326A2 (pt) | formulação seca de uma vacina, uso de uma formulação seca, método para fabricação de uma formulação seca, e, vacina | |
BR112015023507A2 (pt) | vacina estável líquida, e, métodos para vacinar um bovino e para produzir uma vacina estável líquida | |
BRPI0915813A2 (pt) | estabilizante e composição de vacina compreendendo um ou mais flavivírus atenuados vivos | |
CO7270463A2 (es) | Composición farmacéutica acuosa que contiene un agente terapéutico biológico y guanidina o un derivado de la guanidina y una inyección que incluye la composición | |
MY150558A (en) | A pharmaceutical composition comprising rebamipide | |
WO2018091729A3 (en) | Aqueous pharmaceutical formulations | |
EA201991041A1 (ru) | Вакцина против свиного парвовируса и вируса свиного репродуктивного и респираторного синдрома и способы ее получения | |
MX2021004331A (es) | Composiciones estables de semaglutida y usos de las mismas. | |
MX2017016418A (es) | Composiciones de liraglutida de acción prolongada. | |
EA201991023A1 (ru) | Фармацевтическая композиция для парентерального введения, содержащая карглумовую кислоту | |
MX2020006328A (es) | Composición inmunogénica. | |
BR112018004400A2 (pt) | composições de vacina vlp estabilizadas | |
AR092691A1 (es) | Composicion farmaceutica que comprende rebamipida | |
BR112020008482A8 (pt) | Composto leuco | |
BR112017028395A2 (pt) | ?polissacarídeo capsular bacteriano, conjugado, e, composição farmacêutica? | |
BR112012027432A2 (pt) | composições farmacêuticas com agentes antimicrobianos de fosfônio | |
CL2022002207A1 (es) | Formulaciones de composiciones de vacuna contra el virus del dengue (divisional de solicitud 202001463). | |
EA201291463A1 (ru) | Составы для инфузии лантибиотиков типа b | |
BR112022002094A2 (pt) | Composição imunogênica |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
B25A | Requested transfer of rights approved |
Owner name: MERCK SHARP AND DOHME LLC (US) |